Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on April 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E. Lowenthal, the President and CEO of ARS Pharmaceuticals, Inc. (SPRY), sold 100,000 shares of common stock on April 16, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two transactions, each involving 50,000 shares, at weighted average prices of $9.2804 and $9.2797 respectively.
• Following the transactions, Lowenthal directly owns 4,126,822 shares.
• Lowenthal also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Richard Lowenthal Charitable Remainder UniTrust, as well as shares held by his spouse.
• The price range for the first 50,000 shares was between $9.05 and $9.46, and for the second 50,000 shares, it was between $9.05 and $9.47.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transaction was pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a change in the insider's confidence in the company.

Risks

• Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

Insider transactions are routinely monitored by investors as they can provide signals, though sales under 10b5-1 plans are less informative since they are pre-planned.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the pre-planned nature of the sale.

Key Dates